As MPN is an inflammatory disease and the PLT-binding could be mediated by the high levels of inflammation (36), it would be interesting to investigate PLT-binding in MPN patients treated with the clinically approved JAK1/2 inhibitor ruxolitinib, as this drug is a highly anti-inflammatory agent (40). This evidence concerns the gene JAK1 and myeloproliferative disorder.